Lexicon Pharmaceuticals, Inc. (LXRX)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 24 | 0 | 0 | 1 | 31 | 50 | 41 | 38 |
| Operating profit | $m | -49 | -55 | ||||||
| Net profit | $m | -59 | -88 | -102 | -177 | -200 | -50 | -61 | -60 |
| EPS reported | $ | -0.14 | -0.15 | ||||||
| Operating cashflow per share | $ | -0.19 | -0.18 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -0.19 | -0.18 | ||||||
| Free cash flow | $m | -68 | -80 | ||||||
| Net debt | $m | -41 | -139 | ||||||
| Book value equity | $m | 108 | 175 | ||||||
| Book value per share | $ | 0.30 | 0.40 | ||||||
| Number of shares | m | 363.05 | 437.65 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 3.88 | 2.39 | ||||||
| P/S LTM | x | 8.38 | 10.07 | ||||||
| P/FCF LTM | x | -6.15 | -5.24 | ||||||
| EV/EBITDA LTM | x | -10.76 | -8.52 | ||||||
| EV/Sales LTM | x | 8.94 | 25.29 | ||||||
| Earnings Yield LTM | % | -12.06% | -6.02% | ||||||
| FCF Yield | % | -16.25% | -19.09% | ||||||
| Quality | |||||||||
| ROE | % | -46.81% | -40.40% | ||||||
| ROIC | % | -28.71% | -23.00% | ||||||
| Operating margin | % | -98.21% | -1.31% | ||||||
| Gross margin | % | +99.45% | +98.85% | ||||||
| FCF/Sales | % | -136.24% | -192.24% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +60.24% | +33.42% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -1.09 | -1.34 | ||||||
| Net Debt/EBITDA | x | -0.67 | -0.35 | ||||||
| EBIT/Net interest | x | -5.87 | -6.50 | ||||||
| Net debt/market cap | % | +13.33% | +4.99% | ||||||
| Net debt/Equity | x | -0.38 | -0.80 | ||||||
| Gross debt/equity | x | 0.58 | 0.34 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug candidates such as Sotagliflozin, which has successfully concluded Phase III clinical studies for treating both heart failure and type 1 diabetes, and LX9211, currently undergoing Phase II clinical development for neuropathic pain. The firm maintains important strategic collaborations and licensing arrangements with pharmaceutical industry leaders, including Bristol-Myers Squibb Company and Genentech, Inc. Established in 1995, Lexicon Pharmaceuticals, Inc. is based in The Woodlands, Texas.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Lexicon Pharmaceuticals, Inc. (LXRX)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug candidates such as Sotagliflozin, which has successfully concluded Phase III clinical studies for treating both heart failure and type 1 diabetes, and LX9211, currently undergoing Phase II clinical development for neuropathic pain. The firm maintains important strategic collaborations and licensing arrangements with pharmaceutical industry leaders, including Bristol-Myers Squibb Company and Genentech, Inc. Established in 1995, Lexicon Pharmaceuticals, Inc. is based in The Woodlands, Texas.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free